
Aurinia Pharmaceuticals
Quarterly Financials
| Values in thousands | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
|---|---|---|---|---|
Revenue | $83,699 | $83,220 | $77,705 | $77,114 |
Gross Profit | 75,393 | 76,665 | 71,200 | 68,642 |
EBITDA | 44,423 | 54,568 | 49,753 | 47,068 |
EBIT | 39,582 | 49,734 | 44,937 | 42,204 |
Net Income | 31,703 | 37,414 | 34,355 | 210,794 |
Net Change In Cash | 83,699 | 83,220 | 77,705 | 77,114 |
Free Cash Flow | 46,343 | 52,170 | 32,521 | 44,501 |
Cash | 46,145 | 179,832 | 41,008 | 80,213 |
Basic Shares | 135,173 | 133,530 | 137,639 | 138,700 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $283,055 | $235,133 | $175,513 | $134,030 |
Gross Profit | 250,390 | 206,885 | 161,365 | 128,366 |
EBITDA | 127,757 | 31,728 | -63,047 | -108,764 |
EBIT | 118,487 | 12,283 | -74,694 | -111,470 |
Net Income | 287,202 | 5,752 | -78,020 | -108,180 |
Net Change In Cash | 283,055 | 235,133 | 175,513 | 134,030 |
Free Cash Flow | 135,406 | 44,107 | -34,179 | -79,821 |
Cash | 80,213 | 83,433 | 48,875 | 94,172 |
Basic Shares | 138,700 | 146,194 | 143,236 | 141,915 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-09-30 | $0.23 |
2026-06-30 | $0.28 |
2026-03-31 | $0.25 |
2025-12-31 | $0.26 |